Predictive value of dopamine transporter SPECT imaging with [ 123I]PE2I in patients with subtle parkinsonian symptoms

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 2, 2012, Pages 242-250

  Ziebell, Morten ^a   Andersen, Birgitte B ^a   Thomsen, Gerda ^a   Pinborg, Lars H ^a   Karlsborg, Merete ^b   Hasselbalch, Steen G ^a   Knudsen, Gitte M ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

Author keywords

Dopamine transporter; Parkinsonism; Predictive value; SPECT

Indexed keywords

DOPAMINE TRANSPORTER; IODINE 123; N (3 IODOPROP 2 ENYL) 2 BETA CARBOMETHOXY 3BETA (4 METHYLPHENYL)NORTROPANE; NORTROPANE DERIVATIVE; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MINI MENTAL STATE EXAMINATION; NERVE DEGENERATION; PARKINSONISM; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIATE CORTEX;

ADULT; AGED; AGED, 80 AND OVER; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEURODEGENERATIVE DISEASES; NORTROPANES; PARKINSON DISEASE; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84859640438     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1976-9     Document Type: Article

References (34)

1. Benamer HT, Oertel WH, Patterson J, Hadley DM, Pogarell O, Hoffken H, et al. Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations. Mov Disord. 2003;18:977-84. (Pubitemid 37185204)
2. McKeith I, O'Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305-13. (Pubitemid 46367938)
3. Vlaar AM, van Kroonenburgh MJ, Kessels AG, Weber WE. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol. 2007;7:27.
4. Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology. 2001;56:1559-64. (Pubitemid 32544560)
5. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863-72. (Pubitemid 43970103)
6. Tatsch K. Imaging of the dopaminergic system in differential diagnosis of dementia. Eur J Nucl Med Mol Imaging. 2008;35 Suppl 1:S51-7.
7. Emond P, Garreau L, Chalon S, Boazi M, Caillet M, Bricard J, et al. Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(4′-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta-(3′,4′- disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter. J Med Chem. 1997;40:1366-72. (Pubitemid 27198083)
8. Ziebell M, Holm-Hansen S, Thomsen G, Wagner A, Jensen P, Pinborg LH, et al. Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands [123I]FP-CIT and [123I]PE2I. J Nucl Med. 2010;51:1885-91.
9. Booij J, de Jong J, de Bruin K, Knol R, de Win MM, van Eck- Smit BL. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. J Nucl Med. 2007;48:359-66. (Pubitemid 47604917)
10. Ziebell M, Pinborg LH, Thomsen G, de Nijs R, Svarer C, Wagner A, et al. MRI-guided region-of-interest delineation is comparable to manual delineation in dopamine transporter SPECT quantification in patients: a reproducibility study. J Nucl Med Technol. 2010;38:61-8.
11. Ziebell M, Thomsen G, Knudsen GM, de Nijs R, Svarer C, Wagner A, et al. Reproducibility of [123I]PE2I binding to dopamine transporters with SPECT. Eur J Nucl Med Mol Imaging. 2007;34:101-9. (Pubitemid 44885560)
12. Pinborg LH, Ziebell M, Frokjaer VG, de Nijs R, Svarer C, Haugbol S, et al. Quantification of 123I-PE2I binding to dopamine transporter with SPECT after bolus and bolus/infusion. J Nucl Med. 2005;46:1119-27. (Pubitemid 43741073)
13. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533-9. (Pubitemid 47301451)
14. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71:670-6.
15. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56:33-9. (Pubitemid 29046907)
16. Bain P, Brin M, Deuschl G, Elble R, Jankovic J, Findley L, et al. Criteria for the diagnosis of essential tremor. Neurology. 2000;54:S7. (Pubitemid 30390608)
17. Josephs KA, Dickson DW. Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank. Mov Disord. 2003;18:1018-26. (Pubitemid 37185209)
18. Lantos PL. Diagnostic criteria for corticobasal degeneration. J Neurol Neurosurg Psychiatry. 2000;69:705-6.
19. Harbo HF, Finsterer J, Baets J, Van Broeckhoven C, Di Donato S, Fontaine B, et al. EFNS guidelines on the molecular diagnosis of neurogenetic disorders: general issues, Huntington's disease, Parkinson's disease and dystonias. Eur J Neurol. 2009;16:777-85.
20. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734-46. (Pubitemid 47058377)
21. Kalra S, Grosset DG, Benamer HT. Differentiating vascular parkinsonism from idiopathic Parkinson's disease: a systematic review. Mov Disord. 2010;25:149-156.
22. Jasinska-Myga B, Putzke JD, Wider C, Wszolek ZK, Uitti RJ. Depression in Parkinson's disease. Can J Neurol Sci. 2010;37:61-6.
23. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60:387-92. (Pubitemid 36314364)
24. Ballard C, Holmes C, McKeith I, Neill D, O'Brien J, Cairns N, et al. Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease. Am J Psychiatry. 1999;156:1039-45. (Pubitemid 29302797)
25. O'Brien JT, McKeith IG, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Br J Psychiatry. 2009;194:34-9.
26. Marek K, Seibyl J. b-CIT scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA-CIT and CALM-CIT study: long-term imaging assessment. Neurology. 2003;60:abstract 298.
27. Marshall VL, Reininger CB, Marquardt M, Patterson J, Hadley DM, Oertel WH, et al. Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord. 2009;24:500-8.
28. Eerola J, Tienari PJ, Kaakkola S, Nikkinen P, Launes J. How useful is [123I]beta-CIT SPECT in clinical practice? J Neurol Neurosurg Psychiatry. 2005;76:1211-6. (Pubitemid 41208370)
29. Vlaar AM, de Nijs T, Kessels AG, Vreeling FW, Winogrodzka A, Mess WH, et al. Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol. 2008;59:258-66. (Pubitemid 351561095)
30. Knudsen GM, Karlsborg M, Thomsen G, Krabbe K, Regeur L, Nygaard T, et al. Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy. Eur J Nucl Med Mol Imaging. 2004;31:1631-8. (Pubitemid 40104609)
31. Stoffers D, Booij J, Bosscher L, Winogrodzka A, Wolters EC, Berendse HW. Early-stage [123I]beta-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson's disease. Eur J Nucl Med Mol Imaging. 2005;32:689-95. (Pubitemid 40897492)
32. Litvan I, MacIntyre A, Goetz CG, Wenning GK, Jellinger K, Verny M, et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998;55:969-78. (Pubitemid 28335116)
33. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181-4.
34. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009;361:1268-78.